Keyphrases
Adjuvant Therapy
100%
Malignant Melanoma
100%
Sentinel Lymph Node Mapping
100%
Sentinel Lymph Node
66%
Lymph Node Dissection
66%
Regional Lymph Nodes
50%
Primary Melanoma
50%
High Risk
33%
Overall Survival
33%
Melanoma
33%
Lymph Node Status
33%
Extensive Surgery
33%
Isolated Limb Perfusion
33%
Systemic Adjuvant Therapies
33%
Clinically Node-negative
33%
Potential Gains
16%
Prognostic Relevance
16%
Tumor Cells
16%
Low Risk
16%
Prognostic Factors
16%
Distant Metastasis
16%
Quantitative PCR
16%
Immunohistochemical Staining
16%
HE Staining
16%
Phase II Trial
16%
Good Prognosis
16%
High-risk Population
16%
Diagnostic Work-up
16%
Independent Prognostic Factor
16%
Recurrence Risk
16%
Risk for Relapse
16%
Histopathological Examination
16%
Node-negative
16%
Primary Lesion
16%
Lymph Node Positive
16%
Randomized Phase III Trial
16%
Surgical Procedures
16%
Excision
16%
Low Toxicity
16%
Therapy Regimen
16%
Breslow Thickness
16%
High-risk Melanoma
16%
Trial Participation
16%
Wide Local Excision
16%
Tumor Thickness
16%
Systemic Disease
16%
Txn1
16%
Ultra-high Risk
16%
Micrometastatic Disease
16%
General Patients
16%
Multiple Sections
16%
Excision Margins
16%
Medicine and Dentistry
Adjuvant Therapy
100%
Nodular Melanoma
100%
Sentinel-Node Mapping
100%
Sentinel Lymph Node
75%
Retroperitoneal Lymph Node Dissection
50%
Metastatic Carcinoma
25%
Overall Survival
25%
Recurrent Disease
25%
Prognostic Factor
25%
Lymph Node
25%
Limb Perfusion
25%
Neoplasm
12%
Diagnosis
12%
High Risk Population
12%
Tumor Cell
12%
Surgical Margin
12%
Reverse Transcription Polymerase Chain Reaction
12%
Wide Local Excision
12%
Sentinel Node
12%
Surgical Technique
12%
Systemic Disease
12%